Aakaar Medical Technologies Limited
Aakaar Medical Technologies Limited, established in June 2013, specializes in aesthetic medical products and devices, serving dermatologists, plastic surgeons, and aesthetic physicians in India through a B2B model.
What Aakaar files
- Others20
- Investor Meet19
- Updates10
- Important7
- Board Meeting5
- PPTs2
Aakaar Medical Tech addressed an NSE notice regarding a procedural non-compliance. The board confirmed it was inadvertent and implemented corrective measures to ensure strict regulatory adherence.
Aakaar Medical Technologies' Board has approved entry into aesthetics device manufacturing. The company will lease a facility in Pune for contract manufacturing, marking a strategic expansion into a new business segment.
Aakaar has launched the Xelix Partner Clinic Platform to onboard independent dermatology, hair, skin, and aesthetic clinics across India. This strategic initiative aims to build a scalable, asset-light network, boosting demand for Aakaar's products and enhancing market penetration and margins.
Aakaar secured exclusive India distribution agreements with Dermlite/FotoFinder (USA), Croma-Pharma (Austria), APS/Tricopat (Italy/Poland), and TESS/Zishel (South Korea). These deals expand its dermatology and medical aesthetics portfolio, aiming for enhanced revenue visibility and sustained growth in premium segments.
Aakaar Medical Technologies launches Letybo, a USFDA-approved botulinum toxin, for the Indian market. This strategic move into the high-growth medical aesthetics segment boosts credibility and aims for deeper market penetration via flexible pricing.